Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials for ERAS-007, ERAS-601, and ERAS-801 Dosing of the first patient in Phase 1b SEACRAFT-1 trial for naporafenib in RAS Q61X tissue agnostic solid tumors planned for H2 2023, and the dosing of the first patient in the pivotal Phase 3 SEACRAFT-2 trial for naporafenib in NRASm melanoma planned for H1 2024 Robust balance sheet with cash, cash equivalents, and marketable securities of $436 million as of December 31, 2022, and anticipated runway into H2 2025 SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused...

Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Phase 2 trials of VTX958 (TYK2 inhibitor) are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis (UC) is on track to complete enrollment by mid-2023, with topline data expected in H2 2023 Initiated a Phase 2 proof-of-mechanism trial of VTX2735 (peripheral NLRP3 inhibitor) in patients with cryopyrin-associated periodic syndrome (CAPS) Cash, cash equivalents and marketable securities of $356.6 million at the end of 2022 plus an additional $48.4 million in net proceeds raised in Q1 2023 under our “At-the-market” (ATM) program are expected to fund operations into 2025 Ventyx to host conference call and webcast today at 4:30PM ET ENCINITAS, Calif., March 23, 2023 (GLOBE NEWSWIRE) —...

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term designation of an additional monoclonal antibody against SARS-CoV-2 with complementary binding properties to VYD222 for development Well capitalized with $372 million in cash, cash equivalents and marketable securities expected to support operating runway into second half of 2024 Conference call scheduled for Thursday, March 23rd at 4:30 p.m. ET WALTHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the year ended December 31, 2022, and recent business highlights. “2022...

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Written by Customer Service on March 23, 2023. Posted in Earnings Releases And Operating Results.

Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplant Additional trem-cel data expected by year-end 2023; VCAR33ALLO on track for IND submission in first half of 2023 $116M financing extends expected cash runway into Q1 2025 CAMBRIDGE, Mass., March 23, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update. “We are encouraged with the initial proof of concept demonstrated in patients treated in our VBP101 study,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We remain focused on rapid enrollment and plan to share additional clinical data later this...

Quest Resource Holding Corporation Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Written by Customer Service on March 23, 2023. Posted in Public Companies.

THE COLONY, Texas, March 23, 2023 (GLOBE NEWSWIRE) — Quest Resource Holding Corporation (NASDAQ: QRHC) (“Quest”), a national leader in environmental waste and recycling services, today announced financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Highlights Revenue was $62.3 million, a 34.2% increase compared with the fourth quarter of 2021. Gross profit was $10.8 million, a 25.0% increase compared with the fourth quarter of 2021. Gross margin was 17.3% of revenue compared with 18.5% during the fourth quarter of 2021. GAAP net loss per share attributable to common stockholders was $(0.17), compared with $(0.03) per basic and diluted share during the fourth quarter of 2021. Adjusted EBITDA was $2.3 million, a 30.1% decrease compared with the fourth quarter of 2021. Adjusted...

Paltalk, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Continued Sequential Quarterly Improvement in Net Loss and Reduced Operating Expenses JERICHO, NY, March 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Paltalk, Inc. (“Paltalk,” the “Company,” “we,” “our” or “us”) (Nasdaq: PALT), a communications software innovator that powers multimedia social applications, today announced financial and operational results for the fourth quarter and year ended December 31, 2022. Key Financial Highlights for Fourth Quarter Ended December 31, 2022 Compared to Prior Year Period Revenue decreased 10% to $2.8 million Subscription revenue decreased by 8% to $2.7 million Advertising revenue decreased 47% to $0.1 million Net loss increased 9276% to $0.5 million Adjusted EBITDA loss increased 112% to $0.5 million Repurchased 287,719 shares of common stock during the three months ended December 31, 2022...

Atlas Drills 305.5 Meters of Massive Salt in Eastern Step-Out at Great Atlantic

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Great Atlantic Drill Hole CC-9b Great Atlantic Drill Hole CC-9b Great Atlantic Drill Hole Location Map Great Atlantic Drill Hole Location Map Project Map Project Map ST. JOHN’S, Newfoundland and Labrador, March 23, 2023 (GLOBE NEWSWIRE) — Atlas Salt (the “Company” or “Atlas” – TSXV: SALT; OTCQB: REMRF; FSE: 9D00) announces that drill hole CC-9b, collared 250 meters east of CC-4 into an untested part of Great Atlantic, has cut a 336-meter gross interval of salt highlighted by thick sections of massive salt comprising 305.5 meters grading 95.56% sodium chloride (NaCl – salt). Highlights: The first major section (168 meters) of massive salt started at a depth of only 240 meters, and included 6.39 meters of 99.1% salt, further solidifying Great Atlantic as the shallowest deposit in the heart of the robust North American road...

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2022. GeoVax’s leadership will host a live conference call and webcast at 4:30 p.m. Eastern Time today, March 23, 2023, to discuss financial results and provide a general business update. Details are provided below. 2022 CLINICAL TRIAL PROGRESS AND OPERATIONAL DEVELOPMENTS “Our corporate focus continues to be on the advancement of our ongoing clinical programs for our novel Gedeptin® cancer therapy targeting advanced...

Canadian Net REIT Announces the Issuance of Units For Services Rendered and Grant of Performance Units in Relation With Its Unit Compensation Plan

Written by Customer Service on March 23, 2023. Posted in Public Companies.

MONTREAL, March 23, 2023 (GLOBE NEWSWIRE) — (TSX-V: NET.UN) Canadian Net Real Estate Investment Trust (“Canadian Net” or the “Trust”) announces the issuance of 13,329 units of the Trust at a price of $5.88 per unit, which equates to $78,376, and 41,524 deferred trust units as partial compensation for the services rendered by certain members of management and the board of trustees during the fiscal year ended on December 31st, 2022. The issuance of the units and deferred trust units of Canadian Net constitutes a portion of salaries as per the Equity Incentive Plan approved by unitholders on May 25, 2022 (the “Equity Incentive Plan”). Canadian Net also announces the grant of 175,584 performance units (“Performance Units”) to certain members of management under the Equity Incentive Plan. These units will vest in accordance with the...

Nokia Corporation: Repurchase of own shares on 23.03.2023

Written by Customer Service on March 23, 2023. Posted in Public Companies.

Nokia CorporationStock Exchange Release23 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 23.03.2023 Espoo, Finland – On 23 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code) Number of shares Weighted average price / share, EUR* XHEL 276,498 4.31 CEUX 21,127 4.31 AQEU 20,434 4.30 TQEX 4,741 4.30 Total 322,800 4.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU)...

Day: March 23, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice